European parallel importers win another round in their battle with pharmaceutical manufacturers. Reflector reports.
As the UK sterling nears parity with the euro and the competitive prospects for EU economies are not particularly optimistic, there are some positives to take into the new year.
UK biotech leaders have made an unprecedented plea for state funding, claiming that a major cash injection is the only hope for the industry's survival.
Global prescription sales growth of generics slowed to 3.6% in the twelve months ending September 2008, down from 11.4% in 2007, according to a new report by IMS Health.
Factory in north east England to close
A study conducted by business intelligence firm Cutting Edge Information, has discovered that only 59% of pharmaceutical companies have dedicated compliance departments.
GlaxoSmithKline (GSK) is to acquire Genelabs for $57 million through a tender offer of $1.30 per share in cash, a move that should strengthen GSK's efforts to develop novel therapies against the hepatitis C virus.
Sanofi aventis has temporarily suspended sales of the anti-obesity drug Acomplia in Europe, after health authorities warned that the drug's risks outweighed its benefits.
Merck & Co did not have a good week last week — first came the announcement that third-quarter earning are down, then came the news that the company is going to cut 12% of its workforce by the end of 2011.
